Lipum AB Company Description

Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden.

It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases.

Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular.

The company was incorporated in 2010 and is based in Umeå, Sweden.

Lipum AB (publ)

Country	Sweden
Founded	2010
Industry	Biotechnology
Sector	Healthcare
Employees	5
CEO	Ola Sandborgh

Contact Details

Address: TvistevAegen 48C Umeå, 907 36 Sweden
Phone	46 9 03 40 34 30
Website	lipum.se

Stock Details

Ticker Symbol	LIPUM
Exchange	Nasdaq Stockholm
Fiscal Year	January - December
Reporting Currency	SEK
ISIN Number	SE0015660899
SIC Code	2834

Key Executives

Name	Position
Ola Sandborgh	Chief Executive Officer
Prof. Olle Hernell	Co-Founder and Director
Marina Norberg	Chief Financial Officer
Associate Prof. Susanne Lindquist	Co-Founder and Head of Research (CSO)
Dr. Pernilla Abrahamsson	Chief Operating Officer
Dr. Peter Hovstadius	Chief Medical Officer